MedTrace Logo

Role of FAPI PET/MR Combined With Gadoxetate Disodium in Assessing Hepatic Malignancies

NCT06287411 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2024-03-05

No results posted yet for this study

Summary

This study aimed to prospectively evaluate the utility of fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/magnetic resonance (MR) combined with gadoxetate disodium in patients with clinical suspected hepatic malignancies (lesion diameter ≤ 3.0cm), with histopathological findings obtained from biopsy or resected surgical specimens, or follow-up results as reference standards.

Conditions

  • Hepatic Malignancies

Interventions

DIAGNOSTIC_TEST

FAPI PET/MR combined with gadoxetate disodium

Patients with clinical suspected hepatic malignancies will receive the FAPI PET/MR.

Sponsors & Collaborators

  • Xiao Chen

    lead OTHER

Principal Investigators

  • Xiao Chen, Ph.D · Daping Hospital, Army Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06287411 on ClinicalTrials.gov